FIELD: biology.
SUBSTANCE: invention relates to molecular biology, biotechnology, genetic engineering and medicine and is a means for treating conditions of the human body associated with a decrease in the expression of the P4HA1 gene and/or a decrease in the amount of protein spilled 4-hydroxylase alpha 1, based on gene therapy substances with the P4HA1 gene, at least one gene therapeutic substance selected from the group of gene therapeutic substances, each representing a genetic construct based on a vector plasmid comprising the cDNA of the P4HA1 gene, with the coding sequence of the protein spilled 4-hydroxylase alpha 1, with deletions 5'- and 3'-non-translated regions, namely the unmodified cDNA gene obtained from the site P4HA1 SEQ ID No: 1, or a modified cDNA of the P4HA1 gene, wherein the modified cDNA of the P4HA1 gene is SEQ ID No: 2, or SEQ ID No: 3, or SEQ ID No: 4, or SEQ ID No: 5, or SEQ ID No: 6, or SEQ ID No: 7, or a combination of these genetic constructs, each of which also contains regulatory elements that provide a high level of expression of the P4HA1 gene in eukaryotic cells.
EFFECT: invention effectively increases the amount of protein spilled 4-hydroxylase alpha 1 in eukaryotic cells and to obtain a highly effective agent for the treatment of human body conditions associated with a decrease in the level of expression of the P4HA1 gene and/or a decrease in the amount of the prolyl 4-hydroxylase alpha 1 protein.
7 cl, 20 dwg, 18 ex
